The ANXA1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human ANXA1 gene in the well-characterized HeLa cervical adenocarcinoma cell line. This product comprises a genetically diverse pool of cells harboring targeted gene disruptions, providing a robust loss-of-function model to dissect the functions of annexin A1. Unlike clonal isolates, the polyclonal format avoids selection bias and preserves the heterogeneous editing outcomes typical of pooled CRISPR/Cas9 approaches, enabling broader assessment of gene function.
HeLa cells are an immortalized epithelial line derived from a patient with cervical adenocarcinoma and are one of the most extensively used models in biomedical research. These cells retain key signaling pathways including glucocorticoid receptor, MAPK/ERK, PI3K/AKT, and NF-??B, making them highly suitable for studies of inflammation, cancer biology, and drug response. Their robust growth and genetic tractability further facilitate the generation of gene-edited derivatives for functional genomics applications.
Annexin A1 is a calcium-dependent phospholipid-binding protein that transduces glucocorticoid anti-inflammatory signals. Activated by the glucocorticoid receptor (NR3C1), it binds to formyl peptide receptors FPR1/FPR2 and inhibits cytosolic phospholipase A2 (cPLA2) to suppress eicosanoid synthesis. ANXA1 also represses NF-??B, reducing transcription of COX-2 and MMPs, while promoting E-cadherin expression. Interaction with S100A11, EGFR, and actin, together with regulation by PKC phosphorylation, positions ANXA1 at a signaling hub. Crosstalk from EGFR and TGF-?? modulates PI3K/AKT and MAPK/ERK pathways, influencing proliferation, survival, and apoptosis through Bcl-2 family members.
In HeLa cells, ANXA1 knockout abrogates glucocorticoid-mediated anti-inflammatory responses, de-repressing cPLA2 and NF-??B activity. This leads to elevated MMPs and reduced E-cadherin, promoting migration and invasion. The polyclonal knockout population mirrors tumor heterogeneity, enabling studies of variable responses to drugs and growth factors. Given HeLa??s cancer background, this model is particularly suited for dissecting epithelial-mesenchymal transition, metastasis, and drug resistance mechanisms in cervical adenocarcinoma.
Research applications include investigating inflammation resolution, cancer cell migration and invasion, drug resistance, and glucocorticoid signaling. Compatible techniques encompass Western blotting, RT-qPCR, wound healing and Boyden chamber assays, apoptosis assays, immunofluorescence, NF-??B reporter assays, and co-immunoprecipitation to probe interactions with S100A11, FPR1, or EGFR. For more detailed technical support, please contact Ascent Research.
